Evidence map›Paper›PMID 35527500›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2022

[Preparation of purified proteins from fresh Pheretima and their inhibitory effect against pulmonary fibrosis in mice].

S Li, Q Yang, A Zuo, L Tian, J Huo, Y Meng, Q Tang, W Wang

Open access · greenAbstract read
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Effect ofFrontiers in pharmacology · 2022
    Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

S LiSchool of Traditional Chinese Medicine, Southern Medical University//Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics//Guangdong Provincial Engineering Laboratory of Traditional Chinese Medicine, Guangzhou 510515, China.
Q YangSchool of Traditional Chinese Medicine, Southern Medical University//Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics//Guangdong Provincial Engineering Laboratory of Traditional Chinese Medicine, Guangzhou 510515, China.
A ZuoSchool of Traditional Chinese Medicine, Southern Medical University//Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics//Guangdong Provincial Engineering Laboratory of Traditional Chinese Medicine, Guangzhou 510515, China.
L TianInstitute of Chinese Medicine, Heilongjiang Provincial Academy of Chinese Medicine, Harbin 150036, China.
J HuoInstitute of Chinese Medicine, Heilongjiang Provincial Academy of Chinese Medicine, Harbin 150036, China.
Y MengInstitute of Chinese Medicine, Heilongjiang Provincial Academy of Chinese Medicine, Harbin 150036, China.
Q TangSchool of Traditional Chinese Medicine, Southern Medical University//Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics//Guangdong Provincial Engineering Laboratory of Traditional Chinese Medicine, Guangzhou 510515, China.
W WangSchool of Traditional Chinese Medicine, Southern Medical University//Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics//Guangdong Provincial Engineering Laboratory of Traditional Chinese Medicine, Guangzhou 510515, China.
Guangzhou University of Chinese Medicine · CNHeilongjiang University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo develop a convenient method for rapid purification of fresh Pheretima proteins and assess the inhibitory effect of these proteins against pulmonary fibrosis.

methodsThe crude extract of fresh Pheretima was obtained by freeze-drying method and then purified by size exclusion chromatography. The composition of the purified proteins was analyzed by mass spectrometry. MRC-5 cells were treated with 5 ng/mL TGF-β1 alone (model group) or in combination with SB431542 (2 μmol/L) or the purified proteins (13.125 μg/mL), and the cytotoxicity of purified proteins and their inhibitory effects on cell proliferation were detected with CCK8 assay. Flow cytometry was used to detect the changes in cell apoptosis, and the cellular expressions of

resultsWe successfully obtained purified proteins from fresh Pheretima protein by size exclusion chromatography. Treatment with the purified proteins significantly inhibited TGF-β1-induced proliferation of MRC-5 cells (

conclusionThe purified proteins from fresh Pheretima obtained by size exclusion chromatography can inhibit pulmonary fibrosis in mice by regulating the TGF-β/ Smad pathway.

Indexed as

Biological ProductsPulmonary FibrosisAnimalsBleomycinCadherinsCollagen Type ILungMaleMiceMice, Inbred C57BLOligochaetaTransforming Growth Factor beta1VimentinBiological ProductsBleomycinCadherinsCollagen Type ITransforming Growth Factor beta1Vimentinfresh Pheretimamass spectrometrymyofibroblastsprotein purificationtransforming growth factor -β1

Identifiers

PMID35527500
PMCPMC9085584
OpenAlexW4229451414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.